Clinical trials
Completed Acromegaly trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
127 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 10 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 127 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ipsen | 27 |
| Novartis Pharmaceuticals | 13 |
| Pfizer | 7 |
| University of Aarhus | 7 |
| Federico II University | 5 |
| Cedars-Sinai Medical Center | 4 |
| Columbia University | 4 |
| Massachusetts General Hospital | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Camurus AB | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Acromegaly | 127 |
| Pituitary Neoplasms | 11 |
| Dwarfism, Pituitary | 5 |
| Insulin Resistance | 5 |
| Neuroendocrine Tumors | 3 |
| Pituitary ACTH Hypersecretion | 3 |
| Diabetes Mellitus | 2 |
| Gigantism | 2 |
| Glucose Intolerance | 2 |
| Growth Disorders | 2 |
Trials
Showing 1 to 25 of 127. Each trial links to its page on Pharma Observatory.
27 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.